Low clinical penetrance of homozygosity for HFE C282Y: Implications for genetic testing?

European Journal of Clinical Investigation

Volumn 33, Issue 9, 2003, Pages 737-739

  Födinger, Manuela ^a   Sunder Plassmann, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

CLINICAL FEATURE; EDITORIAL; FINLAND; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOSITY; HFE C282Y GENE; HOMOZYGOSITY; HUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

HEMOCHROMATOSIS; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; MEMBRANE PROTEINS; MUTATION; PENETRANCE;

EID: 0042835356     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01224.x     Document Type: Editorial

References (28)

1. Piippo K, Louhija J, Tilvis R, Kontula K. You may live 100 years homozygous for a haemochromatosis gene mutation. Eur J Clin Invest 2003;33:830-831.
2. van Aken MO, de Craen AJM, Gussekloo J, Moghaddam PH, Vandenbroucke JP, Heijmans BT et al. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus study. Eur J Clin Invest 2002;32:750-4.
3. Carru C, Pes GM, Deiana L, Baggio G, Franceschi C, Lio D et al. Association between the HFE mutations and longevity: a study in Sardinian population. Mech Ageing Dev 2003;124:529-32.
4. Willis G, Wimperis JZ, Smith KC, Fellows IW, Jennings BA. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 1999;354:221-2.
5. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-22.
6. Felitti VJ, Beutler E. New developments in hereditary hemochromatosis. Am J Med Sci 1999;318:257-68.
7. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
8. Födinger M, Sunder-Plassmann G. Inherited disorders of iron metabolism. Kidney Int 1999;55 (Suppl. 69):S22-34.
9. 2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8.
10. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-7.
11. Waheed A, Parkkila S, Saarnio J, Fleming RE, Zhou XY, Tomatsu S et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci USA 1999;96:1579-84.
12. Waheed A, Grubb JH, Zhou XY, Tomatsu S, Fleming RE, Costaldi ME et al. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 2002;99:3117-22.
13. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Am J Epidemiol 2001;154:193-206.
14. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-3.
15. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC et al. A survey of 2851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
16. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G
17. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne U et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001;36:1108-15.
18. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD et al. HFE mutations, iron deficiency and overload in 10 500 blood donors. Br J Haematol 2001;114:474-84.
19. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003;101:3347-50.
20. Lee P, Gelbart T, West C, Halloran C, Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002;29:471-87.
21. Roetto A, Totaro A, Cazzola M, Cicilano M, Bosio S, D'Ascola G et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999;64:1388-93.
22. Bomford A. Genetics of haemochromatosis. Lancet 2002;360:1673-81.
23. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002;122:646-51.
24. Schöniger-Hekele M, Müller C, Polli C, Wrba F, Penner E, Ferenci P. Liver pathology in compound heterozygous patients for hemochromatosis mutations. Liver 2002;22:295-301.
25. Brissot P, Moirand R, Jouanolle AM, Guyader D, Le Gall JY, Deugnier Y et al. A genotypic study of 217 unrelated probands diagnosed as 'genetic hemochromatosis' on 'classical' phenotypic criteria. J Hepatol 1999;30:588-93.
26. Tung BY, Emond MJ, Bronner MP, Raaka SD, Coffer SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003;124:318-26.
27. Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A et al. HFE mutations and chronic hepatitis C. H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003;38:335-42.
28. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.